New drug aims to shield patients from Chemo's harsh side effects
Disease control
Not yet recruiting
This study is testing whether a drug called trilaciclib can protect patients' bone marrow from damage during chemotherapy for a type of lung cancer. About 120 people with limited-stage small cell lung cancer will receive either trilaciclib or a placebo before their chemo. The mai…
Phase: PHASE3 • Sponsor: Pharmacosmos A/S • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC